Peregrine Pharmaceuticals (PPHM): 50% Upside on this Biotechnology Stock

Page 1 of 2

The patent cliff has positively impacted the valuations of small biopharmaceutical companies due to their acquisition potential. Peregrine Pharmaceuticals (NASDAQ:PPHM) is currently trading at a 50% discount to my estimated target price of $4. I believe the stock will bounce back as the market has still not adjusted for the recent positive news in company disclosures. It is also a major acquisition candidate and I believe it will be a nice fit for Pfizer Inc. (NYSE:PFE) and Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA).

Peregrine Pharmaceuticals (NASDAQ:PPHM)Peregrine Pharmaceuticals (NASDAQ:PPHM) is a biopharmaceutical company focused on the discovery, development, and commercialization of biopharmaceutical products. The company is focused on the development of monoclonal antibodies for the cure of cancer and viral infections.

Pipeline

The company has an interesting pipeline with 3 primary candidates under various phases of clinical trials.

Bavituximab

This candidate is currently in Phase II clinical trials. The drug is being tested in 3 different randomized Phase II clinical trials for the treatment of NSCLC (Non-small Lung Cancer) and pancreatic cancer. Bavituximab is a monoclonal antibody that targets phosphatidylserine and has demonstrated the ability to treat various oncology indications.

Cotara

It is the lead candidate of Peregrine for their Tumor Necrosis Therapy (TNT) and is in Phase II clinical trials. The interim results have been good as the percentage of patients alive at 6 months, 12 months and 24 months were 73%, 38% and 19%, respectively. Moreover, two patients under treatment with Cotara were still alive after 3 years.

PNG650

The company is also in preclinical trial stage for its tumor imaging candidate PNG650. According to company disclosures it has initiated an open label, single center trial at Washington University. The trials will involve 12 healthy subjects which will be given a single dose of the imaging agent.

Valuations

The stock is currently trading at a 55% discount to its mean sell side target price of $4.50 and at a 30% discount to its lowest sell side target price. The stock has traded as high as $5.50 in the last 52 weeks, a 65% upside to current levels. Peregrine lost almost 50% of its value when the company announced in September that there were major discrepancies in the study for its star drug Bavituximab. I have a $4 target price on the stock based on the sell side estimates and past valuations.

Since then the stock has gained some of its value due to the positive announcement by the company that most of the problems indicated with Phase II trial have been resolved, and the drug is all set to enter phase III. According to the company’s announcement the review has found discrepancies with the 1 mg/kg trial and no problems with the 3mg/kg trial. I believe it is only a matter of time before the stock will move back to its value before the negative announcement on Bavituximab ruined its valuations.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

The 10 Most Peaceful Countries in the World

5 Big Reasons Communism Failed

The 15 Most Famous Carl Icahn Quotes

10 Scary Animals that are Actually Harmless

The 8 Most Famous Singer-Actors in Entertainment

The 10 Longest Wars of All Time

The 13 Worst Looking Foods that Taste Great

The 6 Most Gruesome Injuries Suffered During a Sports Match

The 20 Biggest Contracts in MLB History

The 7 Worst Blown Calls in Sports History

7 Free Ways to Advertise Your Business Online

The 18 Best R&B Songs of the 90’s

The 10 Most Dangerous States to be a Cop

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!